SCHEMBL5364167

SCHEMBL5364167

Oc1ccc(C=NNC(=S)Nc2cccc3ccccc23)c(O)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.71
KDM4E B2RXH2 5/20 0.71
L3MBTL1 Q9Y468 5/20 0.71
GAA P10253 5/20 0.71
NPC1 O15118 1/20 0.71
HTT P42858 3/20 0.56
LMNA P02545 2/20 0.56
HPGD P15428 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
PTPN1 P18031 1/20 0.54
KMT2A Q03164 5/20 0.53
MEN1 O00255 4/20 0.53
DHODH Q02127 1/20 0.53
ALDH1A1 P00352 3/20 0.53
RRM1 P23921 1/20 0.52
RRM2 P31350 1/20 0.52
RRM2B Q7LG56 1/20 0.52
NFKB1 P19838 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5364159 1.00 MAPT (0.71) MAPTKDM4EL3MBTL1GAANPC1
SCHEMBL5364129 0.85 MAPT (0.53) MAPTKDM4EL3MBTL1GAANPC1
SCHEMBL5364134 0.85 MAPT (0.53) MAPTKDM4EL3MBTL1GAANPC1
SCHEMBL5362936 0.85 PTPN1 (0.56) MAPTKDM4EL3MBTL1GAANPC1
SCHEMBL5362944 0.85 PTPN1 (0.56) MAPTKDM4EL3MBTL1GAANPC1
SCHEMBL12453292 0.76 MAPT (0.56) MAPTKDM4EGAANPC1LMNA
SCHEMBL15965636 0.72 MEN1 (0.52) MAPTKDM4EL3MBTL1GAANPC1
SCHEMBL1275812 0.71 KMT2A (0.72) KDM4EGAANPC1SMN1; SMN2KMT2A
SCHEMBL13641767 0.70 L3MBTL1 (0.66) MAPTKDM4EL3MBTL1GAANPC1
SCHEMBL27797248 0.70 L3MBTL1 (0.66) MAPTKDM4EL3MBTL1GAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US claimed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP claimed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP claimed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK MAPT 4635/4885KDM4E 3460/4885L3MBTL1 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.